Dominic Borie
Chief Tech/Sci/R&D Officer at KYVERNA THERAPEUTICS, INC.
Net worth: 7 M $ as of 2024-04-29
Profile
Dominic Borie is currently the President-Research & Development at Kyverna Therapeutics, Inc. He previously worked as an Executive Director at Allogene Therapeutics, Inc., a Medical Director at Amgen, Inc., a Senior Medical Director at Genentech, Inc., and a VP, Head-External Research & Development at Horizon Therapeutics Plc.
Dr. Borie also served as the Director-Transplantation Immunology Laboratory at Stanford University.
He holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from North Carolina State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-06 | 449,210 ( 1.04% ) | 7 M $ | 2024-04-29 |
Dominic Borie active positions
| Companies | Position | Start |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-10-12 |
Former positions of Dominic Borie
| Companies | Position | End |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| ALLOGENE THERAPEUTICS, INC. | Director/Board Member | - |
Training of Dominic Borie
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Dominic Borie
